Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here is how CanFite Biopharma Ltd (CANF) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that pre-clinical studies with skin cells, modeling psoriasis in humans, show that Piclidenoson, the Company's drug candidate for the treatment of psoriasis, destroys pathological skin cells. The Company's scientists reported that in a cell culture

Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today that it will hold one-on-one virtual investor meetings during the J.P. Morgan Healthcare Conference. The Company recently reported a complete response to Namodenoson in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer, in its

Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Issues Letter to Shareholders

Can-Fite Issues Letter to Shareholders

Can-Fite (CANF) files patent applications in several countries for treating all advanced solid tumors. The filing comes after Can-Fite's drug cleared all tumor lesions in advanced liver cancer.

Can-Fite (CANF) Files Patent Applications for Namodenoson

Can-Fite BioPharma is rising on Wednesday following positive Phase 2 data on its liver cancer treatment. Can it help turn CANF stock around?

CANF Stock: The Cancer-Fighting News Sending Can-Fite Higher Today

American Virtual Cloud Technologies

NRX Pharmaceuticals

MingZhu Logistics Holdings

These penny stocks are on the move, early and here's why. The post Hot Penny Stocks To Watch Before Today's Opening Bell appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks To Watch Before Today's Opening Bell

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Company is filing new patent applications in several countries for the treatment of all advanced solid tumors based on new clinical data showing that a patient with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, w

Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors

PETACH TIKVA, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the agreement by an healthcare-focused institutional investor to exercise certain warrants to purchase up to an aggregate of 150,000,000 ordinary shares represented by 5,000,000 American Depositary Shares (ADSs) having an exercise price of $2.00 per ADS issued by Can-Fite in August 2021, at an exercise price of $2.00 per ADSs.

Can-Fite Announces Exercise of Warrants for Cash Proceeds of $10 Million

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson experienced a Complete Response (CR). Under treatment with Namodenoson, the patient has now survived five years.

Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient

The stock price of Can Fite Biopharma (NYSEAMERICAN: CANF) increased by over 70% during intraday trading today. This is why it happened.

Can Fite Biopharma Stock (CANF): Why The Price Surged Today

Can-Fite BioPharma (CANF) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial for liver cancer. The post CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher Today appeared first on InvestorPlace.

CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher Today

PETACH TIKVA, Israel--(BUSINESS WIRE)--Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Digital Ally Inc

Mereo Biopharma Group Plc - ADR

OPKO Health

Progenity

5 penny stocks to buy for under $5 right now. Are they worth the risk?

5 Penny Stocks To Buy For Under $5 This Week

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week cycle of treatment with Piclidenoson at the beginning of January 2022.  Piclidenoson is a novel, first-in-class A3 adenosine receptor agonist (A3AR) small molecule.

Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022

Can-Fite's Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022

Cannabis-focused biotech company Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) reported its financial results Friday for nine months ended September 30, 2021, with revenues of $650,000, compared to $610,000 in the same period of 2020.

Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update

Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021

Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021

Can-Fite BioPharma Ltd (NYSE: CANF) has commenced a safety and efficacy study of Piclidenoson to treat osteoarthritis in dogs.  Safety results are expected in Q1 2022, and efficacy data is expected in Q4 2022.

Can-Fite's Kickstarts Piclidenoson Study For Canine Osteoarthritis

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite's Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis. The Study conducted and costs covered by Vetbiolix.

Can-Fite's Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference

Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Findings on Cannabis Compound's Inhibition of Liver Cancer Published in HEPATOLOGY and will be Presented at the AASLD's The Liver Meeting®

Can-Fite's Findings on Cannabis Compound's Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD's The Liver Meeting® 2021 Conference

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its patent titled "An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation" has been granted in Hong Kong and Mexico, and has received a notice of allowance in Japan. This patent addresses the use of the A3 Adenosine Recept

Can-Fite's NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit

News for Can-Fite BioPharma Ltd. Stock (CANF)